Company intelligence / Profile preview

Zyomyx

Fremont, California, United States

Ownership: Private
Development stage: Other

Overview

Zyomyx developed a novel, rapid point-of-care diagnostic for CD4 T-cell counting that achieved technical milestones and was field validated, but failed to reach full commercialization due to evolving HIV treatment guidelines, rising costs, and lack of sufficient investment.

Therapeutic areas: OncologyImmunologyWomen's HealthInfectious Diseases
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

Bill & Melinda Gates FoundationMylanClinton Health Access InitiativeImperial College London (CD4 Initiative)

Beyond the preview

Go deeper on Zyomyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zyomyx.

Explore the full profile